vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and FVCBankcorp, Inc. (FVCB). Click either name above to swap in a different company.
Beta Bionics, Inc. is the larger business by last-quarter revenue ($27.6M vs $16.9M, roughly 1.6× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 56.6%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
BBNX vs FVCB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $16.9M |
| Net Profit | $-21.9M | — |
| Gross Margin | 59.5% | — |
| Operating Margin | -47.4% | 43.7% |
| Net Margin | -79.3% | — |
| Revenue YoY | 56.6% | 4377.5% |
| Net Profit YoY | 23.6% | — |
| EPS (diluted) | $-0.49 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $16.9M | ||
| Q3 25 | $27.3M | $416.0K | ||
| Q2 25 | $23.2M | $15.8M | ||
| Q1 25 | $17.6M | $382.0K | ||
| Q4 24 | — | $378.0K | ||
| Q3 24 | — | $412.0K | ||
| Q2 24 | — | $415.0K |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-14.2M | $5.6M | ||
| Q2 25 | $-16.9M | $5.7M | ||
| Q1 25 | $-28.7M | $5.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $4.2M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | — | ||
| Q3 25 | 55.5% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 50.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | 43.7% | ||
| Q3 25 | -62.5% | — | ||
| Q2 25 | -85.5% | 45.9% | ||
| Q1 25 | -105.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | — | ||
| Q3 25 | -52.1% | 1341.1% | ||
| Q2 25 | -72.6% | 36.0% | ||
| Q1 25 | -162.5% | 1352.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1133.3% | ||
| Q2 24 | — | 1001.2% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $0.31 | ||
| Q3 25 | $-0.33 | $0.31 | ||
| Q2 25 | $-0.39 | $0.31 | ||
| Q1 25 | $-0.93 | $0.28 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | — | $0.25 | ||
| Q2 24 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.2M | $253.6M |
| Total Assets | $304.4M | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | — | ||
| Q3 25 | $228.7M | — | ||
| Q2 25 | $249.7M | — | ||
| Q1 25 | $231.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $253.6M | ||
| Q3 25 | $294.8M | $249.8M | ||
| Q2 25 | $301.6M | $243.2M | ||
| Q1 25 | $313.8M | $242.3M | ||
| Q4 24 | — | $235.4M | ||
| Q3 24 | — | $230.8M | ||
| Q2 24 | — | $226.5M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $2.3B | ||
| Q3 25 | $330.0M | $2.3B | ||
| Q2 25 | $330.0M | $2.2B | ||
| Q1 25 | $338.0M | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $23.9M |
| Free Cash FlowOCF − Capex | — | $23.8M |
| FCF MarginFCF / Revenue | — | 140.7% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $40.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $23.9M | ||
| Q3 25 | $-8.7M | $7.6M | ||
| Q2 25 | $-13.6M | $3.3M | ||
| Q1 25 | $-20.0M | $5.4M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $1.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | $23.8M | ||
| Q3 25 | $-10.0M | $7.6M | ||
| Q2 25 | $-15.4M | $3.3M | ||
| Q1 25 | $-20.3M | $5.4M | ||
| Q4 24 | — | $18.1M | ||
| Q3 24 | — | $4.6M | ||
| Q2 24 | — | $1.5M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | 140.7% | ||
| Q3 25 | -36.7% | 1818.0% | ||
| Q2 25 | -66.2% | 20.8% | ||
| Q1 25 | -115.1% | 1413.6% | ||
| Q4 24 | — | 4786.0% | ||
| Q3 24 | — | 1121.8% | ||
| Q2 24 | — | 361.2% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 0.3% | ||
| Q3 25 | 4.7% | 0.2% | ||
| Q2 25 | 7.7% | 0.1% | ||
| Q1 25 | 1.9% | 4.2% | ||
| Q4 24 | — | 37.3% | ||
| Q3 24 | — | 14.1% | ||
| Q2 24 | — | 12.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
